235 related articles for article (PubMed ID: 34105823)
21. Current status of targeted therapies for mantle cell lymphoma.
Chang JE; Kahl BS
Drugs; 2011 Dec; 71(17):2307-26. PubMed ID: 22085387
[TBL] [Abstract][Full Text] [Related]
22. Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.
Trněný M; Lamy T; Walewski J; Belada D; Mayer J; Radford J; Jurczak W; Morschhauser F; Alexeeva J; Rule S; Afanasyev B; Kaplanov K; Thyss A; Kuzmin A; Voloshin S; Kuliczkowski K; Giza A; Milpied N; Stelitano C; Marks R; Trümper L; Biyukov T; Patturajan M; Bravo MC; Arcaini L;
Lancet Oncol; 2016 Mar; 17(3):319-331. PubMed ID: 26899778
[TBL] [Abstract][Full Text] [Related]
23. Advances and issues in mantle cell lymphoma research: report of the 2014 Mantle Cell Lymphoma Consortium Workshop.
Kahl BS; Gordon LI; Dreyling M; Gascoyne RD; Sotomayor EM
Leuk Lymphoma; 2015; 56(9):2505-11. PubMed ID: 25944379
[TBL] [Abstract][Full Text] [Related]
24. How I manage mantle cell lymphoma: indolent versus aggressive disease.
Wilson MR; Barrett A; Cheah CY; Eyre TA
Br J Haematol; 2023 Apr; 201(2):185-198. PubMed ID: 36807902
[TBL] [Abstract][Full Text] [Related]
25. The shifting therapeutic paradigm for relapsed/refractory mantle cell lymphoma.
Arun Kumar S; Gao J; Patel SA
Leuk Res; 2023 Nov; 134():107385. PubMed ID: 37672954
[TBL] [Abstract][Full Text] [Related]
26. Management of relapsed/refractory mantle cell lymphoma: a review of current therapeutic strategies.
Zaja F; Federico M; Vitolo U; Zinzani PL
Leuk Lymphoma; 2014 May; 55(5):988-98. PubMed ID: 23865835
[TBL] [Abstract][Full Text] [Related]
27. The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma.
Arkwright R; Pham TM; Zonder JA; Dou QP
Expert Opin Drug Discov; 2017 Feb; 12(2):225-235. PubMed ID: 27917682
[TBL] [Abstract][Full Text] [Related]
28. Personalized approaches for treatment-naïve mantle cell lymphoma.
Qualls D; Kumar A
Expert Rev Hematol; 2023 Feb; 16(2):95-107. PubMed ID: 36748785
[TBL] [Abstract][Full Text] [Related]
29. Novel treatment for mantle cell lymphoma - impact of BTK inhibitors and beyond.
Gribbin C; Chen J; Martin P; Ruan J
Leuk Lymphoma; 2024 Jan; 65(1):1-13. PubMed ID: 37800170
[TBL] [Abstract][Full Text] [Related]
30. Management of mantle cell lymphoma: key challenges and next steps.
Williams ME; Dreyling M; Winter J; Muneer S; Leonard JP
Clin Lymphoma Myeloma Leuk; 2010 Oct; 10(5):336-46. PubMed ID: 21030346
[TBL] [Abstract][Full Text] [Related]
31. Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop.
Williams ME; Connors JM; Dreyling MH; Gascoyne RD; Kahl BS; Leonard JP; Press OW; Wilson WH
Leuk Lymphoma; 2011 Jan; 52(1):24-33. PubMed ID: 21133727
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond.
Zhou Y; Zhang L; Romaguera J; Delasalle K; Han X; Du X; Kwak L; Yi Q; Wang M
Am J Hematol; 2008 Feb; 83(2):144-9. PubMed ID: 17722077
[TBL] [Abstract][Full Text] [Related]
33. Mantle cell lymphoma: biological insights and treatment advances.
Leonard JP; Williams ME; Goy A; Grant S; Pfreundschuh M; Rosen ST; Sweetenham JW
Clin Lymphoma Myeloma; 2009 Aug; 9(4):267-77. PubMed ID: 19717376
[TBL] [Abstract][Full Text] [Related]
34. Combating relapsed and refractory Mantle cell lymphoma with novel therapeutic armamentarium: Recent advances and clinical prospects.
Raghani NR; Shah DD; Shah TS; Chorawala MR; Patel RB
Crit Rev Oncol Hematol; 2023 Oct; 190():104085. PubMed ID: 37536448
[TBL] [Abstract][Full Text] [Related]
35. Update on the molecular pathogenesis and targeted approaches of mantle cell lymphoma: summary of the 12th annual conference of the European Mantle Cell Lymphoma Network.
Dreyling M; Amador V; Callanan M; Jerkeman M; Le Gouill S; Pott C; Rule S; Zaja F;
Leuk Lymphoma; 2015 Apr; 56(4):866-76. PubMed ID: 25015778
[TBL] [Abstract][Full Text] [Related]
36. Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group.
Yoon DH; Cao J; Chen TY; Izutsu K; Kim SJ; Kwong YL; Lin TY; Thye LS; Xu B; Yang DH; Kim WS
J Hematol Oncol; 2020 Mar; 13(1):21. PubMed ID: 32183871
[TBL] [Abstract][Full Text] [Related]
37. Treatment Landscape of Relapsed/Refractory Mantle Cell Lymphoma: An Updated Review.
Al-Mansour M
Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):e1019-e1031. PubMed ID: 36068158
[TBL] [Abstract][Full Text] [Related]
38. Novel agents for mantle cell lymphoma: molecular rational and clinical data.
Sarkozy C; Ribrag V
Expert Opin Investig Drugs; 2020 Jun; 29(6):555-566. PubMed ID: 32321318
[TBL] [Abstract][Full Text] [Related]
39. Novel therapeutic targets in mantle cell lymphoma.
Martin P; Leonard JP
Expert Opin Ther Targets; 2007 Jul; 11(7):929-40. PubMed ID: 17614761
[TBL] [Abstract][Full Text] [Related]
40. Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2013 Dec; 88(12):1082-8. PubMed ID: 24273091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
